In itself, I’m not sure if it would matter to a large player whether the situation is a few million in losses or a few million in profit, as long as the direction is clear. I suppose they are primarily buying an AI model that can be integrated into their own product to ensure the competitiveness of that product (e.g., a scanner). Jukka has repeatedly said in interviews that AI is ultimately the “carrot” that brings the benefit and what everyone is interested in, which could create that competitive advantage.
Revenue in itself builds credibility; the product is, in a way, more validated, more tested, and in practice probably better known for a company with high sales.
Fortunately, Aiforia is starting to have quite good references on the clinical side, even though clinical revenue has only just started moving!
Well, if you value it in relation to revenue/profit—which doesn’t exist—then certainly. If, on the other hand, you consider that someone wants those AI models, then the market cap is 15 times cheaper than the entity with fewer models that was just acquired. By buying early, one could still get a good AI at a reasonable price; a profitable company in a few years will already be more expensive 